so what is next Carter, page-8

Yep pogues, can't disagree that zolpi Europe is the front runner for next to drop, but I'm not a huge fan of zolpi as I've mentioned before.

The thing I like about Sud02 is that it's a real drug used for real medical needs. It's also a global deal which should attract higher up-fronts than the slim pickens offered up in previous regional deals. I don't think it will be any where near what some of the numbers are that have been spruiked previously, see below, but something around 5-8 million in upfronts and 20 million in milestones would have to spark some fire in an otherwise lack-lustre share price.

Just speculatin' of course.